Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 10,492 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT03922724
View directory record Official record
Conditions
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Interventions
ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Early Phase 1 Interventional

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

NCT04740580
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Glycine, N-acetylcysteine, Alanine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
55 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

NCT05445323
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions
Low dose LX2006, Mid Dose LX2006, High Dose LX2006
Genetic
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 2 Interventional

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
BFB759, Placebo
Biological · Drug
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Encino, California • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

NCT06741397
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, New formulation of CAB LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

NCT03179917
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Pembrolizumab, Involved Site Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

NCT03830918
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Biological · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Dietary Guidelines 3 Diet Patterns Study (DG3D): Phase 2

NCT05254496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Dietary Intervention Classes
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Not applicable Interventional

An Evaluation of Epic EHR AI Outpatient Chart Summarization

NCT07438743
View directory record Official record
Conditions
Quality Improvement
Interventions
GenAI Chart Summarization
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 3 Interventional

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225
View directory record Official record
Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk
Procedure · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
409
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 3 Interventional

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

NCT03104517
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
AMDC-USR (iltamiocel), Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 2 Interventional

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

NCT04060017
View directory record Official record
Conditions
Autism Spectrum Disorder, Language Disorders
Interventions
Levoleucovorin Calcium, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
30 Months to 60 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Not applicable Interventional

App Delivered Brief Mindfulness Intervention for Surgical Patients

NCT05433389
View directory record Official record
Conditions
Pain, Anxiety State, Depressive State
Interventions
Breath Counting, Body Scan, Mindful Breathing, Mindfulness of Pain, Mindful Savoring
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

NCT04636697
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Intramuscular injection, Intramuscular vaccine
Drug · Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years and older
Enrollment
30,918 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
45
States / cities
Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Quality of Recovery From Mastectomy With and Without PECS Blocks

NCT05795413
View directory record Official record
Conditions
Post Operative Pain, Quality of Recovery After Mastectomy
Interventions
Mastectomy with PECS blocks, Liposomal bupivacaine
Procedure · Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RCT2100, Placebo, Ivacaftor
Drug · Other
Lead sponsor
ReCode Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Reducing Alcohol Involved Sexual Violence in Higher Education

NCT05185440
View directory record Official record
Conditions
Sexual Violence, Drinking Heavy
Interventions
GIFTSS Training, Learning Collaborative, Provider Scripts
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 24 Years
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 1 Interventional

CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

NCT03684889
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
SCRI-huCAR19v1, SCRI-huCAR19v2
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs

NCT04301518
View directory record Official record
Conditions
Preterm Labor, Preterm Birth
Interventions
Multimodal intervention strategy
Other
Lead sponsor
Sera Prognostics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
18
States / cities
San Diego, California • New Haven, Connecticut • Newark, Delaware + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Alcohol and the Social Brain: An Alcohol-Administration Hyperscanning Study

NCT06687525
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Use Disorder, Alcohol Intoxication, Alcohol; Harmful Use, Alcoholism, Binge Drinking
Interventions
Not listed
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 30 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Phase 2 Interventional

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma
Interventions
Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Not applicable Interventional

Autoimmune Intervention Mastery Course Study

NCT05057676
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, Fibromyalgia, Post Acute Sequelae of COVID-19, Cancer in Remission With Persisting Fatigue
Interventions
Immediate Autoimmune Intervention Mastery Course (AIM), Immediate Question and Answer sessions. (AIM Q and A sessions), Delayed Autoimmune Intervention Mastery Course (delayed AIM course), Delayed AIM Question and Answer sessions
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 5, 2026, 2:26 AM EST
Active, not recruiting Not applicable Interventional

Black Church Treatment Study

NCT04580810
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
CBT4CBT in the Black Church
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 5, 2026, 2:26 AM EST